Impact of concomitant heart failure on outcomes in patients undergoing percutaneous coronary interventions: analysis of the Melbourne Interventional Group registry.

Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature Review. Cardiovasc Ther (2016) 0.80

Impact of heart failure on outcome after percutaneous coronary intervention: is it the patient or the intervention? Eur J Heart Fail (2011) 0.75

Phase 4 Studies in Heart Failure - What is Done and What is Needed? Curr Cardiol Rev (2016) 0.75

Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40

Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet (2007) 6.88

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet (2006) 6.42

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 6.26

Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (2010) 5.30

B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med (2010) 4.42

Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38

Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation (2010) 3.65

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53

Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation (2013) 3.44

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30

Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med (2009) 2.97

Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation (2011) 2.88

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation (2011) 2.71

Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm (2012) 2.60

Trends in elective knee arthroscopies in a population-based cohort, 2000-2009. Med J Aust (2012) 2.58

Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med (2002) 2.52

HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci U S A (2008) 2.52

Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29

Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ (2012) 2.23

Renal denervation in moderate to severe CKD. J Am Soc Nephrol (2012) 2.21

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation (2002) 2.20

Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med (2007) 2.20

Modular control of human walking: a simulation study. J Biomech (2009) 2.20

Wnt signaling mediates reorientation of outer hair cell stereociliary bundles in the mammalian cochlea. Development (2003) 2.18

B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med (2009) 2.18

Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain (2003) 2.18

Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension (2012) 2.17

History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension (2008) 2.09

Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation (2012) 2.07

Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil (2011) 2.05

Evaluating the value and impact of the Victorian Audit of Surgical Mortality. ANZ J Surg (2013) 2.05

Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study. Circulation (2009) 2.02

Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches. J Am Coll Cardiol (2011) 2.02

High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation (2009) 2.00

Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail (2005) 1.96

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J (2013) 1.95

Neighbourhood fast food outlets and obesity in children and adults: the CLAN Study. Int J Pediatr Obes (2008) 1.93

Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain (2006) 1.92

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA (2007) 1.91

Clinical service organisation for heart failure. Cochrane Database Syst Rev (2012) 1.90

Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation (2005) 1.86

A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol (2008) 1.85

Acute left ventricular remodeling following myocardial infarction: coupling of regional healing with remote extracellular matrix expansion. JACC Cardiovasc Imaging (2012) 1.83

Children's fruit and vegetable intake: associations with the neighbourhood food environment. Prev Med (2007) 1.83

Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol (2013) 1.83

Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens (2011) 1.80

Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv (2004) 1.76

Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension (2010) 1.74

Characteristics and treatment of headache after traumatic brain injury: a focused review. Am J Phys Med Rehabil (2006) 1.73

Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol (2012) 1.71

Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol (2008) 1.69

Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension (2009) 1.67

Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail (2011) 1.67

Does prior percutaneous coronary intervention adversely affect early and mid-term survival after coronary artery surgery? JACC Cardiovasc Interv (2009) 1.61

Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am J Cardiol (2005) 1.60

An embolic deflection device for aortic valve interventions. JACC Cardiovasc Interv (2010) 1.60

Validation of the EuroSCORE model in Australia. Eur J Cardiothorac Surg (2006) 1.60

Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation (2004) 1.59

May-Thurner syndrome in patients with cryptogenic stroke and patent foramen ovale: an important clinical association. Stroke (2009) 1.58

Modulation of remifentanil-induced postinfusion hyperalgesia by the β-blocker propranolol in humans. Pain (2012) 1.57

Trauma resuscitation errors and computer-assisted decision support. Arch Surg (2011) 1.57

Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United kingdom experience. J Pediatr (2007) 1.56

The WHICH? trial: rationale and design of a pragmatic randomized, multicentre comparison of home- vs. clinic-based management of chronic heart failure patients. Eur J Heart Fail (2011) 1.55

Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension (2012) 1.54

Do features of public open spaces vary according to neighbourhood socio-economic status? Health Place (2007) 1.54

Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hypertens (2013) 1.54

Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol (2009) 1.53

Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am J Hematol (2003) 1.53

Survival of elderly patients undergoing percutaneous coronary intervention for acute myocardial infarction complicated by cardiogenic shock. JACC Cardiovasc Interv (2009) 1.52

Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension (2012) 1.52

Outcomes after percutaneous coronary intervention of ostial lesions in the era of drug-eluting stents. Catheter Cardiovasc Interv (2009) 1.51

Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation. Int J Cardiol (2010) 1.50

Reliability of elbow stretch reflex assessment in chronic post-stroke hemiparesis. Clin Neurophysiol (2005) 1.50

Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur J Heart Fail (2011) 1.50

Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction. Eur J Heart Fail (2013) 1.49

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med (2005) 1.49

Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial. Eur J Heart Fail (2012) 1.49

Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study. Int J Cardiol (2010) 1.48

Multidetector computed tomography in transcatheter aortic valve implantation. JACC Cardiovasc Imaging (2011) 1.47

Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci (2002) 1.47

Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging (2003) 1.47

Impaired pulmonary diffusing capacity and hypoxia in heart failure correlates with central sleep apnea severity. Chest (2008) 1.46